Site search
2898 results for '' found
Client_contribution_-_CHSP.pdf
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia (N
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults with Chronic Primary Immune Thrombocytopenia (N
/
A Phase 3 Study Comparing Daratumumab, VELCADE [bortezomib], Lenalidomide, and Dexamethasone [D-VRd] vs VELCADE, Lenalidomide, and Dexamethasone [VRd] in Subjects with Previously Untreated Multip
A Phase 3 Study Comparing Daratumumab, VELCADE [bortezomib], Lenalidomide, and Dexamethasone [D-VRd] vs VELCADE, Lenalidomide, and Dexamethasone [VRd] in Subjects with Previously Untreated Multip
/
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms (NCT07008118)
A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms (NCT07008118)
/
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory
A Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory
/
Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients with Heart Failure and Reduced Ejection Fraction (NCT06812533)
Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients with Heart Failure and Reduced Ejection Fraction (NCT06812533)
/
Guanethidine for Pulmonary Hypertension with Heart Failure with a Preserved Ejection Fraction [PH-HFpEF] (ACTRN12625000817448)
Guanethidine for Pulmonary Hypertension with Heart Failure with a Preserved Ejection Fraction [PH-HFpEF] (ACTRN12625000817448)
/
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (NCT068585
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE) (NCT068585
/
Minderoo_Foundation_Wellness_Centre_-_Newsletter_Nov_2025.pdf
Alfred_Health_Annual_Report_2024-2025.pdf